Evommune (NYSE:EVMN) Upgraded by Clear Str to Strong-Buy Rating

Posted by Teresa Graham on Mar 20th, 2026

Clear Str upgraded shares of Evommune (NYSE:EVMN – Free Report) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research analysts have also issued reports on EVMN. Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. HC Wainwright dropped their target price on shares of Evommune from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday. The Goldman Sachs Group upgraded shares of Evommune to a “buy” rating in a research note on Wednesday, January 7th. Leerink Partners began coverage on shares of Evommune in a research note on Monday, December 1st. They set an “outperform” rating and a $42.00 price objective on the stock. Finally, Royal Bank Of Canada raised shares of Evommune to a “moderate buy” rating in a research note on Tuesday, March 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $47.17.

View Our Latest Stock Analysis on Evommune

Evommune Trading Down 3.2%

NYSE:EVMN opened at $23.32 on Tuesday. The firm has a fifty day moving average of $23.26. The company has a market capitalization of $839.76 million and a PE ratio of -2.89. Evommune has a twelve month low of $13.89 and a twelve month high of $33.20.

Evommune (NYSE:EVMN – Get Free Report) last posted its earnings results on Thursday, March 5th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Hedge Funds Weigh In On Evommune

Several large investors have recently modified their holdings of EVMN. Burkehill Global Management LP bought a new stake in Evommune during the 4th quarter valued at about $856,000. TD Asset Management Inc purchased a new position in Evommune in the 4th quarter worth approximately $764,000. State Street Corp bought a new position in Evommune in the 4th quarter valued at approximately $539,000. Oxford Asset Management LLP purchased a new stake in Evommune during the 4th quarter valued at $335,000. Finally, XTX Topco Ltd purchased a new position in shares of Evommune in the fourth quarter worth $321,000.

Key Stories Impacting Evommune

Here are the key news stories impacting Evommune this week:

Positive Sentiment: Clear Street initiated coverage with a Buy recommendation, giving independent buying interest and analyst coverage that can support demand for the shares. Clear Street initiates coverage of Evommune (EVMN) with buy recommendation
Positive Sentiment: Evommune’s Relative Strength (RS) rating rose to 91, indicating stronger price momentum versus peers — a technical positive that can attract momentum-focused buyers. Stocks to watch: Evommune sees RS rating rise to 91
Neutral Sentiment: HC Wainwright lowered its price target from $65 to $50 but maintained a “Buy” rating — the cut reduces upside vs. prior targets but still implies substantial upside from current levels, leaving investor reaction mixed. Benzinga coverage of HC Wainwright price target change
Negative Sentiment: HC Wainwright materially reduced near‑term and full‑year EPS forecasts: Q1 2026 to ($0.83), Q2 to ($0.71), Q3 to ($0.71), Q4 to ($0.75) and FY2026 to ($3.00) (down from prior estimates). The shop also issued a FY2027 EPS forecast of ($3.30). Those downgrades signal worsening profitability/visibility and are the primary driver of today’s weakness. HC Wainwright Issues Pessimistic Forecast for Evommune (NYSE:EVMN) Stock Price

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.